4YFN 2022
This week we will be attending the 4YFN in Barcelona as a company selected by @icex and @red.es. Do not hesitate to stop by our stand on Monday and Tuesday. 4YFN 2022 event.
Stand 6C37.5
CA04 Antidoby vs Pancreatic cancer
CA04 - Antidody against pancreatic cancer
We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
Icex Next
CancerAppy SL en el marco del Programa ICEX Next, ha
contado con el apoyo de ICEX y con la cofinanciación del fondo europeo FEDER. La finalidad de este apoyo es contribuir al desarrollo internacional de la empresa y de su entorno.
CA02/03 Target Identification vs NSCLC
CA02/03 - Target Identification
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
Total Funding Raised
Total Funding Raised - 690K
CancerAppy closed 2021 with €690K total raised.